Press Release|Articles|October 30, 2025
Camber Launches Abacavir and Lamivudine Tablets, USP
Listen
0:00 / 0:00
Key Takeaways
- Camber Pharmaceuticals introduces Abacavir and Lamivudine Tablets, USP, for treating HIV-1 infection, enhancing access to essential treatments.
- The tablets contain 600 mg Abacavir and 300 mg Lamivudine, supplied in bottles of 30 tablets.
Advertisement
Continuing its mission to expand access to essential treatments, Camber Pharmaceuticals introduces Abacavir and Lamivudine Tablets, USP [a-BAK-a-veer-and-la-MIV-yoo-deen] to its portfolio.
Abacavir/Lamivudine Tablets, USP are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection.
Camber's Abacavir and Lamivudine Tablets, USP (600 mg/300 mg) are supplied in bottles of 30 tablets.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Positive Phase 2a Trial Supports FDA Clearance of StemCyte’s HPC Therapy for Long COVID Patients
2
Centanafadine for Treatment of ADHD in Children, Adolescents, and Adults Accepted By FDA for Priority Review
3
Carbachol and Brimonidine Tartrate Combination Eye Drop Receives FDA Approval for Presbyopia
4
Plant-Based Foods, Even If Ultra-Processed, Can Reduce Risk of Diabetes
5